|本期目录/Table of Contents|

[1]魏晓辉,苏智祥,陈文娟,等.PD-1单抗治疗晚期非小细胞肺癌血清IL-27与预后相关性[J].中华肺部疾病杂志,2023,(05):650-653.[doi:10.3877/cma.j.issn.1674-6902.2023.05.009]
点击复制

PD-1单抗治疗晚期非小细胞肺癌血清IL-27与预后相关性(PDF)

《中华肺部疾病杂志》[ISSN:1006-6977/CN:61-1281/TN]

卷:
期数:
2023年05期
页码:
650-653
栏目:
临床研究
出版日期:
2023-10-20

文章信息/Info

Title:
-
作者:
魏晓辉1; 苏智祥1; 陈文娟1; 张燕军1; 刘 佳2; 丁彩霞3; 王云梅1; 侯银银1
710061 陕西,陕西省肿瘤医院肿瘤内科1、胸外科2、病理科3
Author(s):
-
关键词:
白细胞介素-27;  纳武单抗;  非小细胞肺癌;  预后
Keywords:
-
分类号:
R734.2
DOI:
10.3877/cma.j.issn.1674-6902.2023.05.009
摘要:
目的 分析经程序性死亡受体1(programmed death 1, PD-1)单抗二线治疗晚期非小细胞肺癌(non-small cell lung cancer, NSCLC)血清白细胞介素(IL)-27与预后相关性。方法 选择2019年6月至2022年4月我院收治的纳武单抗治疗晚期NSCLC患者107例。第1次注射纳武单抗前1 d,采用酶联免疫吸附实验(ELISA)测量基线血清IL-27水平,每2个治疗周期后评估治疗反应,8周内出现进展为早期进展者; 获得部分反应或疾病稳定者为应答者。结果 早期进展者基线血清IL-27水平低于应答者86.72(55.38,117.94)pg/ml vs. 184.41(116.81,273.29)pg/ml,Z=-5.329,P<0.001,预测早期进展者工作特征曲线下面积(AUC)0.829(95%CI:0.749～0.910,P<0.001)。基线血清IL-27水平与活检组织PD-L1表达正相关(r=0.523,P<0.001),与中性粒细胞计数(r=-0.402,P<0.001)、中性粒细胞和淋巴细胞比值(r=-0.343,P<0.001)、血清C反应蛋白水平(r=-0.309,P=0.001)、肺免疫预后指数(LIPI)(r=-0.247,P=0.010)负相关,与晚期肺癌炎症指数正相关(r=0.311,P=0.001)。年龄、基线血清IL-27水平是纳武单抗治疗晚期NSCLC患者OS的预后因素(P<0.05)。基线血清IL-27≤108.63 ng/ml的中位OS期短(P<0.05)。结论 血清IL-27可能成为评估晚期NSCLC接受二线纳武单抗治疗具有临床意义。
Abstract:
-

参考文献/References:

1 吴国明, 钱桂生. 非小细胞肺癌靶向治疗研究进展及新理念[J/CD]. 中华肺部疾病杂志(电子版), 2019, 12(4): 405-408.
2 Doroshow DB, Sanmamed MF, Hastings K, et al. Immunotherapy in Non-Small Cell Lung Cancer: Facts and HopesLung Cancer Immunotherapy: Facts and Hopes[J]. Clin Cancer Res, 2019, 25(15): 4592-4602.
3 Mamdani H, Matosevic S, Khalid AB, et al. Immunotherapy in Lung Cancer: Current Landscape and Future Directions[J]. Front Immunol, 2022, 13: 823618.
4 Wang L, Zhao D, Qin K, et al. Effect and biomarker of Nivolumab for non-small-cell lung cancer[J]. Biomed Pharmacother, 2019, 117: 109199.
5 Spigel DR, Vicente D, Ciuleanu TE, et al. Second-line nivolumab in relapsed small-cell lung cancer: CheckMate 331☆[J]. Ann Oncol, 2021, 32(5): 631-641.
6 Franzin R, Netti GS, Spadaccino F, et al. The use of immune checkpoint inhibitors in oncology and the occurrence of AKI: where do we stand?[J]. Front Immunol, 2020, 11: 574271-574291.
7 Riano I, Abuali I, Sharma A, et al. Role of Neoadjuvant Immune Checkpoint Inhibitors in Resectable Non-Small Cell Lung Cancer[J]. Pharmaceuticals(Basel), 2023, 16(2): 233-245.
8 鲁德玕, 鲁嘉萌, 姬晓青, 等. IL-27与T细胞免疫[J]. 国际免疫学杂志, 2019, 42(6): 655-661.
9 Carbotti G, Nikpoor AR, Vacca P, et al. IL-27 mediates HLA class I up-regulation, which can be inhibited by the IL-6 pathway, in HLA-deficient Small Cell Lung Cancer cells[J]. J Exp Clin Cancer Res, 2017, 36(1): 1-12.
10 Petretto A, Carbotti G, Inglese E, et al. Proteomic analysis uncovers common effects of IFN-γ and IL-27 on the HLA class I antigen presentation machinery in human cancer cells[J]. Oncotarget, 2016, 7(45): 72518-72537.
11 Airoldi I, Tupone M G, Esposito S, et al. Interleukin-27 re-educates intratumoral myeloid cells and down-regulates stemness genes in non-small cell lung cancer[J]. Oncotarget, 2015, 6(6): 3694-3708.
12 Shiroyama T, Suzuki H, Tamiya M, et al. Pretreatment advanced lung cancer inflammation index(ALI)for predicting early progression in nivolumab-treated patients with advanced non-small cell lung cancer[J]. Cancer Med, 2018, 7(1): 13-20.
13 Mezquita L, Auclin E, Ferrara R, et al. Association of the lung immune prognostic index with immune checkpoint inhibitor outcomes in patients with advanced non-small cell lung cancer[J]. JAMA Oncol, 2018, 4(3): 351-357.
14 Shiroyama T, Suzuki H, Tamiya M, et al. Pretreatment advanced lung cancer inflammation index(ALI)for predicting early progression in nivolumab-treated patients with advanced non-small cell lung cancer[J]. Cancer Med, 2018, 7(1): 13-20.
15 刘 磊, 李福霞, 禚孝丽, 等. 免疫检查点抑制剂疗效预测生物标志物在非小细胞肺癌中的研究进展[J]. 中华肿瘤防治杂志, 2022, 29(22): 1628-1635.
16 Del Re M, Cucchiara F, Rofi E, et al. A multiparametric approach to improve the prediction of response to immunotherapy in patients with metastatic NSCLC[J]. Cancer Immunol Immunother, 2021, 70(6): 1667-1678.
17 Liu Y, Zugazagoitia J, Ahmed FS, et al. Immune Cell PD-L1 Colocalizes with Macrophages and Is Associated with Outcome in PD-1 Pathway Blockade Therapy[J]. Clin Cancer Res, 2020, 26(4): 970-977.
18 Niu M, Yi M, Li N, et al. Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC[J]. Exp Hematol Oncol, 2021, 10(1): 1-13.
19 Oitabén A, Fonseca P, Villanueva MJ, et al. Emerging Blood-Based Biomarkers for Predicting Immunotherapy Response in NSCLC[J]. Cancers(Basel), 2022, 14(11): 2626-2647.
20 Hao L, Hu Y, Hu J, et al. Case report: A squamous cell lung carcinoma patient who responded to neoadjuvant immunochemotherapy but died from anastomosis leakage or/and irAEs: Immune microenvironment and genomic features changes[J]. Front Oncol, 2021, 11: 674328.
21 Kim DH, Kim HR, Choi YJ, et al. Exosomal PD-L1 promotes tumor growth through immune escape in non-small cell lung cancer[J]. Exp Mol Med, 2019, 51(8): 1-13.
22 Niu M, Liu Y, Yi M, et al. Biological characteristics and clinical significance of soluble PD-1/PD-L1 and exosomal PD-L1 in cancer[J]. Front Immunol, 2022, 13: 827921.
23 Sadagopan A, Michelakos T, Boyiadzis G, et al. Human leukocyte antigen class I antigen-processing machinery upregulation by anticancer therapies in the Era of checkpoint inhibitors: A review[J]. JAMA Oncol, 2022, 8(3): 462-473.
24 Fabbi M, Carbotti G, Ferrini S. Dual roles of IL-27 in cancer biology and immunotherapy[J]. Mediators Inflamm, 2017: 1-14.
25 Wang Q, Liu J. Regulation and immune function of IL-27[J]. Adv Exp Med Biol, 2016, 941: 191-211.
26 Carbotti G, Barisione G, Airoldi I, et al. IL-27 induces the expression of IDO and PD-L1 in human cancer cells[J]. Oncotarget, 2015, 6(41): 43267-43280.
27 Zhao S, Ren S, Jiang T, et al. Low-dose apatinib optimizes tumor microenvironment and potentiates antitumor effect of PD-1/PD-L1 blockade in lung cancer apatinib potentiates anti-PD-1/PD-L1 effect in lung cancer[J]. Cancer Immunol Res, 2019, 7(4): 630-643.
28 Gao Y, Yang J, Cai Y, et al. IFN-γ-mediated inhibition of lung cancer correlates with PD-L1 expression and is regulated by PI3K-AKT signaling[J]. Int J Cancer, 2018, 143(4): 931-943.
29 Liu J, Li S, Zhang S, et al. Systemic immune-inflammation index, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio can predict clinical outcomes in patients with metastatic non-small-cell lung cancer treated with nivolumab[J]. J Clin Lab Anal, 2019, 33(8): e22964.
30 Emens LA, Middleton G. The interplay of immunotherapy and chemotherapy: harnessing potential synergies[J]. Cancer Immunol Res, 2015, 3(5): 436-443.

备注/Memo

备注/Memo:
基金项目: 陕西省重点研发计划项目(2022SF-261)
通信作者: 苏智祥, Email: suyisheng986@163.com
更新日期/Last Update: 2023-10-20